|
US4350687A
(en)
|
1980-02-10 |
1982-09-21 |
Research Corporation |
Platelet derived cell growth factor
|
|
JPS60146833A
(ja)
|
1984-01-10 |
1985-08-02 |
Green Cross Corp:The |
モノクロ−ナル抗体製剤
|
|
JPS6178731A
(ja)
|
1985-05-20 |
1986-04-22 |
Green Cross Corp:The |
加熱処理免疫グロブリン製剤
|
|
CA1327161C
(en)
|
1987-09-01 |
1994-02-22 |
Mitsugu Kobayashi |
Lyophilized pharmaceutical composition of neocarzinostatin derivative
|
|
SE8801537D0
(sv)
|
1988-04-26 |
1988-04-26 |
Ellco Food Ab |
Cellodlingsmedium samt forfarande for dess framstellning
|
|
US5252713A
(en)
|
1988-09-23 |
1993-10-12 |
Neorx Corporation |
Polymeric carriers for non-covalent drug conjugation
|
|
JPH04504253A
(ja)
|
1989-03-27 |
1992-07-30 |
セントカー・インコーポレーテツド |
ＩｇＭ抗体の安定化のための配合物
|
|
US5116944A
(en)
|
1989-12-29 |
1992-05-26 |
Neorx Corporation |
Conjugates having improved characteristics for in vivo administration
|
|
US5216130A
(en)
|
1990-05-17 |
1993-06-01 |
Albany Medical College |
Complex for in-vivo target localization
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
US5260308A
(en)
|
1991-11-06 |
1993-11-09 |
Mayo Foundation For Medical Education And Research |
Method to increase permeability of the blood-nerve/brain barriers to proteins
|
|
US5736137A
(en)
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
|
US6537579B1
(en)
|
1993-02-22 |
2003-03-25 |
American Bioscience, Inc. |
Compositions and methods for administration of pharmacologically active compounds
|
|
PT910382E
(pt)
|
1996-04-26 |
2003-10-31 |
Genaera Corp |
Esqualamina em combinacao com outros agentes anti-cancro para o tratamento de tumores
|
|
GB9613182D0
(en)
|
1996-06-24 |
1996-08-28 |
Nycomed Imaging As |
Method
|
|
US5728541A
(en)
|
1996-07-12 |
1998-03-17 |
Precision Therapeutics, Inc. |
Method for preparing cell cultures from biologial specimens for chemotherapeutic and other assays
|
|
US6416967B2
(en)
|
1996-07-12 |
2002-07-09 |
Precision Therapeutics, Inc. |
Method of using multicellular particulates to analyze malignant or hyperproliferative tissue
|
|
US8853260B2
(en)
|
1997-06-27 |
2014-10-07 |
Abraxis Bioscience, Llc |
Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
|
|
PT1023050E
(pt)
|
1997-06-27 |
2013-12-04 |
Abraxis Bioscience Llc |
Novas formulações de agentes farmacológicos, métodos para a sua preparação e métodos para a sua utilização
|
|
US7041301B1
(en)
|
1997-11-07 |
2006-05-09 |
Mayo Foundation For Medical Education And Research |
Interferon immunotherapy
|
|
US6616925B1
(en)
|
1998-04-02 |
2003-09-09 |
I.D.M. Immuno-Designed Molecules |
Combined preparation for the treatment of neoplasic diseases or of infectious diseases
|
|
US7112409B2
(en)
|
1999-01-29 |
2006-09-26 |
Center For Molecular Medicine And Immunology |
Method of determining cytokine dosage for myelosuppressive state
|
|
US7534866B2
(en)
|
2005-10-19 |
2009-05-19 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
|
JP2001072589A
(ja)
|
1999-07-06 |
2001-03-21 |
Toagosei Co Ltd |
制癌剤
|
|
US6420378B1
(en)
|
1999-10-15 |
2002-07-16 |
Supergen, Inc. |
Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
|
|
DE10132502A1
(de)
|
2001-07-05 |
2003-01-23 |
Gsf Forschungszentrum Umwelt |
Angriff auf Tumorzellen mit fehlender, niedriger oder anormaler MHC-Expression durch kombinieren von nicht MHC-Restringierten T-Zellen/NK-Zellen und MHC-Restringierten Zellen
|
|
BR0309254A
(pt)
|
2002-04-12 |
2005-03-01 |
Medarex Inc |
Uso de um anticorpo anti-ctla-4
|
|
IL166156A0
(en)
|
2002-07-09 |
2006-01-15 |
Point Therapeutics Inc |
Boroproline compound combination therapy
|
|
EP1539234A4
(en)
|
2002-09-05 |
2006-02-15 |
Medimmune Inc |
METHOD FOR PREVENTING OR TREATING CELL MALIGNITY BY ADMINISTERING CD2 ANTAGONISTS
|
|
AU2003265948B8
(en)
|
2002-09-06 |
2009-09-03 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
|
|
EP2359859A1
(en)
|
2002-12-09 |
2011-08-24 |
Abraxis BioScience, LLC |
Compositions comprising albumin nanoparticles and methods of delivery of pharmacological agents
|
|
US20050043233A1
(en)
|
2003-04-29 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
|
|
AR046510A1
(es)
|
2003-07-25 |
2005-12-14 |
Regeneron Pharma |
Composicion de un antagonista de vegf y un agente anti-proliferativo
|
|
ATE459364T1
(de)
|
2003-10-22 |
2010-03-15 |
Univ Johns Hopkins |
Verbesserte bakteriolyse-kombinationstherapie für die behandlung von tumoren
|
|
DK1763356T3
(da)
|
2004-04-22 |
2008-10-13 |
Lilly Co Eli |
Sammensætning der omfatter et survivinantisenseoligonuckleotid og gemcitabin til behandling af cancer
|
|
EP2301963A1
(en)
|
2004-09-23 |
2011-03-30 |
Vasgene Therapeutics, Inc. |
Polypeptide compounds for inhibiting angiogenesis and tumor growth
|
|
CN101438252A
(zh)
|
2004-10-07 |
2009-05-20 |
爱莫里大学 |
多功能纳米粒子共轭体及其应用
|
|
US20070166388A1
(en)
|
2005-02-18 |
2007-07-19 |
Desai Neil P |
Combinations and modes of administration of therapeutic agents and combination therapy
|
|
CA2598239C
(en)
|
2005-02-18 |
2019-10-29 |
Abraxis Bioscience, Inc. |
Nanoparticulate formulations of taxanes and carrier proteins for use in combination chemotherapy
|
|
US8735394B2
(en)
|
2005-02-18 |
2014-05-27 |
Abraxis Bioscience, Llc |
Combinations and modes of administration of therapeutic agents and combination therapy
|
|
CN101355928B
(zh)
|
2005-04-26 |
2013-05-22 |
卫材R&D管理株式会社 |
用于癌症免疫疗法的组合物和方法
|
|
US10183076B2
(en)
|
2005-05-16 |
2019-01-22 |
Resdevco Research And Development Co. L |
Topical compositions for treatment of irritation of mucous membranes
|
|
US7771751B2
(en)
|
2005-08-31 |
2010-08-10 |
Abraxis Bioscience, Llc |
Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
|
|
AU2006284657B2
(en)
|
2005-08-31 |
2012-07-19 |
Abraxis Bioscience, Llc |
Compositions and methods for preparation of poorly water soluble drugs with increased stability
|
|
US7776832B2
(en)
|
2006-04-21 |
2010-08-17 |
Gem Pharmaceuticals, Llc |
Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines
|
|
PL2081595T3
(pl)
|
2006-09-26 |
2019-11-29 |
Genmab As |
Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych
|
|
WO2008047272A2
(en)
|
2006-10-17 |
2008-04-24 |
Koninklijke Philips Electronics N.V. |
Device for amplification and detection of nucleic acids
|
|
EP1914242A1
(en)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
|
GB0621973D0
(en)
|
2006-11-03 |
2006-12-13 |
Philogen Spa |
Binding molecules and uses thereof
|
|
US20100112077A1
(en)
|
2006-11-06 |
2010-05-06 |
Abraxis Bioscience, Llc |
Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
|
|
CA2668836A1
(en)
|
2006-11-07 |
2008-05-15 |
Dow Agrosciences Llc |
Sprayable, controlled-release, male annihilation technique (mat) formulation and insect control method
|
|
MX2009006466A
(es)
|
2006-12-13 |
2009-06-26 |
Schering Corp |
Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina.
|
|
DK2117520T3
(en)
|
2006-12-14 |
2019-01-07 |
Abraxis Bioscience Llc |
BREAST CANCER THERAPY BASED ON HORMON RECEPTOR STATUS WITH NANOPARTICLES INCLUDING TAXAN
|
|
LT2481409T
(lt)
|
2007-03-07 |
2018-10-25 |
Abraxis Bioscience, Llc |
Nanodalelės, apimančios rapamiciną ir albuminą, kaip priešvėžinį agentą
|
|
EP2125002A4
(en)
|
2007-03-14 |
2011-02-23 |
Mayo Foundation |
TREATMENT OF SKIN CANCER
|
|
WO2009005673A1
(en)
|
2007-06-28 |
2009-01-08 |
Schering Corporation |
Anti-igf1r
|
|
WO2009043159A1
(en)
|
2007-10-01 |
2009-04-09 |
The Hospital For Sick Children |
Neural tumor stem cells and methods of use thereof
|
|
WO2009055343A2
(en)
|
2007-10-22 |
2009-04-30 |
Schering Corporation |
Fully human anti-vegf antibodies and methods of using
|
|
KR101502267B1
(ko)
|
2007-11-09 |
2015-03-18 |
페레그린 파마수티컬즈, 인크 |
항-ｖｅｇｆ 항체 조성물 및 방법
|
|
EP3266453A1
(en)
|
2008-07-03 |
2018-01-10 |
Mayo Foundation for Medical Education and Research |
Treating cancer
|
|
CN102159247A
(zh)
|
2008-07-30 |
2011-08-17 |
日东电工株式会社 |
药物载体
|
|
WO2010014784A2
(en)
|
2008-08-01 |
2010-02-04 |
Bristol-Myers Squibb Company |
Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
|
|
EP2321408A4
(en)
|
2008-08-04 |
2013-04-17 |
Allocure Inc |
MESENCHYMAL STROMAZELL POPULATIONS AND PROCESS FOR THEIR INSULATION AND USE
|
|
WO2010075540A1
(en)
|
2008-12-23 |
2010-07-01 |
Burnham Institute For Medical Research |
Methods and compositions for synaphically-targeted treatment for cancer
|
|
CN102482347B
(zh)
|
2009-01-12 |
2017-04-26 |
希托马克斯医疗有限责任公司 |
修饰抗体组合物及其制备和使用方法
|
|
US9636384B2
(en)
|
2009-04-06 |
2017-05-02 |
Mayo Foundation For Medical Education And Research |
Methods for making polymeric nanoparticle-polypeptide complex
|
|
BRPI1014160A2
(pt)
|
2009-04-10 |
2015-08-25 |
Abraxis Bioscience Llc |
Formulações de nanopartículas e aplicações das mesmas
|
|
US8571805B2
(en)
|
2009-04-10 |
2013-10-29 |
Pharmaco-Kinesis Corporation |
Method and apparatus for detecting and regulating vascular endothelial growth factor (VEGF) by forming a homeostatic loop employing a half-antibody biosensor
|
|
WO2010124009A2
(en)
|
2009-04-21 |
2010-10-28 |
Schering Corporation |
Fully human anti-vegf antibodies and methods of using
|
|
WO2010136492A2
(en)
|
2009-05-28 |
2010-12-02 |
Glaxo Group Limited |
Antigen-binding proteins
|
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
|
KR20120101050A
(ko)
|
2009-11-05 |
2012-09-12 |
더 유에이비 리서치 파운데이션 |
기저형 유전자형 암의 치료 방법
|
|
WO2011057709A1
(en)
|
2009-11-13 |
2011-05-19 |
Merck Patent Gmbh |
Anti integrin antibodies linked to nanoparticles loaded with chemotherapeutic agents
|
|
MY166014A
(en)
|
2010-06-07 |
2018-05-21 |
Abraxis Bioscience Llc |
Combination therapy methods for treating proliferative diseases
|
|
EP2625525A4
(en)
|
2010-10-08 |
2014-04-02 |
Abraxis Bioscience Llc |
SPARC MICRO ENVIRONMENT SIGNATURE, PLASMA SPARC AND LDH AS PROGNOSTIC BIOMARKERS IN THE TREATMENT OF CANCER
|
|
US20130281377A1
(en)
|
2010-12-23 |
2013-10-24 |
Mayo Foundation For Medical Education And Research |
Treating multiple myeloma
|
|
US20120283290A1
(en)
|
2011-05-06 |
2012-11-08 |
Amicus Therapeutics Inc. |
Quantitation of gl3 in urine
|
|
PT2707030T
(pt)
*
|
2011-05-09 |
2020-05-22 |
Mayo Found Medical Education & Res |
Tratamentos de cancro
|
|
US20130028895A1
(en)
|
2011-07-27 |
2013-01-31 |
Gerald Wulf |
Exosome inhibiting agents and uses thereof
|
|
WO2013043569A1
(en)
|
2011-09-20 |
2013-03-28 |
Vical Incorporated |
Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
|
|
US9931121B2
(en)
|
2011-10-17 |
2018-04-03 |
University Of Utah Research Foundation |
Methods and devices for connecting nerves
|
|
AU2012335543C1
(en)
|
2011-11-09 |
2017-12-14 |
Beijing Cotimes Biotech Co., Ltd., |
HER3 antibodies and uses thereof
|
|
PT3210627T
(pt)
|
2012-07-12 |
2023-03-23 |
Hangzhou Dac Biotech Co Ltd |
Conjugados de moléculas de ligação celular com agentes citotóxicos
|
|
US11471486B2
(en)
|
2012-09-04 |
2022-10-18 |
Inven2 As |
Selective and controlled expansion of educated NK cells
|
|
EP2903610B1
(en)
|
2012-10-01 |
2021-11-03 |
Mayo Foundation For Medical Education And Research |
Cancer treatments
|
|
US10342869B2
(en)
|
2012-12-07 |
2019-07-09 |
The Regents Of The University Of California |
Compositions comprising anti-CD38 antibodies and lenalidomide
|
|
US20140186447A1
(en)
|
2012-12-28 |
2014-07-03 |
Abraxis Bioscience, Llc |
Nanoparticle compositions of albumin and paclitaxel
|
|
CA2900668A1
(en)
|
2013-02-11 |
2014-08-14 |
Abraxis Bioscience, Llc |
Treatment of melanoma with nanoparticles comprising paclitaxel
|
|
LT3049441T
(lt)
|
2013-09-27 |
2020-02-10 |
F. Hoffmann-La Roche Ag |
Anti-pdl1 antikūnų kompozicija
|
|
MY189089A
(en)
*
|
2013-12-17 |
2022-01-25 |
Genentech Inc |
Methods of treating cancers using pd-1 axis binding antagonists and taxanes
|
|
SMT201900544T1
(it)
*
|
2014-05-13 |
2019-11-13 |
Medimmune Ltd |
Anticorpi anti-b7-h1 e anti-ctla-4 per trattare il cancro del polmone non a piccole cellule
|
|
JP6695286B2
(ja)
|
2014-06-13 |
2020-05-20 |
メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ |
リンパ腫の処置
|
|
JP6600651B2
(ja)
|
2014-06-16 |
2019-10-30 |
マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ |
骨髄腫の治療
|
|
DK3204413T3
(da)
|
2014-10-06 |
2019-12-09 |
Mayo Found Medical Education & Res |
Bærerantistofsammensætninger og fremgangsmåder til fremstilling og anvendelse heraf
|
|
US9446148B2
(en)
|
2014-10-06 |
2016-09-20 |
Mayo Foundation For Medical Education And Research |
Carrier-antibody compositions and methods of making and using the same
|
|
WO2016059220A1
(en)
|
2014-10-16 |
2016-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Tcr-activating agents for use in the treatment of t-all
|
|
KR20170101925A
(ko)
*
|
2014-12-02 |
2017-09-06 |
셀진 코포레이션 |
병용 요법
|
|
GB201500374D0
(en)
*
|
2015-01-09 |
2015-02-25 |
Immutep S A |
Combined preparations for the treatment of cancer
|
|
US20180155429A1
(en)
*
|
2015-05-28 |
2018-06-07 |
Bristol-Myers Squibb Company |
Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
|
|
WO2017176265A1
(en)
|
2016-04-06 |
2017-10-12 |
Mayo Foundation For Medical Education And Research |
Carrier-binding agent compositions and methods of making and using the same
|
|
TW201707725A
(zh)
|
2015-08-18 |
2017-03-01 |
美國馬友醫藥教育研究基金會 |
載體－抗體組合物及其製造及使用方法
|
|
CN108290944B
(zh)
|
2015-08-18 |
2022-05-17 |
梅约医学教育与研究基金会 |
载体结合剂组合物及其制备和使用方法
|
|
TW201713360A
(en)
|
2015-10-06 |
2017-04-16 |
Mayo Foundation |
Methods of treating cancer using compositions of antibodies and carrier proteins
|
|
WO2017120501A1
(en)
|
2016-01-07 |
2017-07-13 |
Mayo Foundation For Medical Education And Research |
Methods of treating cancer with interferon
|
|
WO2017139698A1
(en)
|
2016-02-12 |
2017-08-17 |
Mayo Foundation For Medical Education And Research |
Hematologic cancer treatments
|
|
EP3432926A4
(en)
|
2016-03-21 |
2019-11-20 |
Mayo Foundation for Medical Education and Research |
METHOD FOR REDUCING THE TOXICITY OF CHEMOTHERAPEUTICS
|
|
US11878061B2
(en)
|
2016-03-21 |
2024-01-23 |
Mayo Foundation For Medical Education And Research |
Methods for improving the therapeutic index for a chemotherapeutic drug
|
|
US10618969B2
(en)
|
2016-04-06 |
2020-04-14 |
Mayo Foundation For Medical Education And Research |
Carrier-binding agent compositions and methods of making and using the same
|
|
EP3493854B1
(en)
|
2016-08-05 |
2023-10-04 |
Mayo Foundation for Medical Education and Research |
Modified antibody-albumin nanoparticle complexes for cancer treatment
|
|
EP3506950A1
(en)
|
2016-09-01 |
2019-07-10 |
Mayo Foundation for Medical Education and Research |
Methods and compositions for targeting t-cell cancers
|
|
US11548946B2
(en)
|
2016-09-01 |
2023-01-10 |
Mayo Foundation For Medical Education And Research |
Carrier-PD-L1 binding agent compositions for treating cancers
|
|
KR20230010817A
(ko)
|
2016-09-06 |
2023-01-19 |
메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 |
파클리탁셀-알부민-결합제 조성물 및 그의 사용 및 제조 방법
|
|
MX2019002626A
(es)
|
2016-09-06 |
2019-10-02 |
Walmart Apollo Llc |
Selector de imagenes de una pieza de un producto.
|
|
WO2018048815A1
(en)
|
2016-09-06 |
2018-03-15 |
Nantibodyfc, Llc |
Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
|
|
JP7142915B2
(ja)
|
2016-10-28 |
2022-09-28 |
株式会社Ｓ＆Ｋバイオファーマ |
ラクトフェリン／アルブミン融合タンパク質及びその製造方法
|